QA teams are increasingly expected to oversee risk-based clinical trial operations with clear rationale, proportionality, and traceable decisions.
Traditional QA models often relied heavily on retrospective review and broad audit coverage.
ICH E6(R3) shifts expectations toward:
ongoing oversight
proportionate review
continuous evaluation
documented rationale
QA is becoming a strategic oversight function that helps organizations determine:
More vendors, more systems, more data streams.
Operational teams may apply oversight differently across studies.
Organizations increasingly need governance around AI-supported decisions.
RBQM helps QA teams focus attention proportionally.
Instead of treating all activities equally, oversight becomes aligned with study-specific risk and critical processes.
This improves:
QA teams also gain clearer visibility into:
The recent FDA warning letter involving AI reliance and missing process validation requirements illustrates an important signal for regulated industries.
Clinical trial organizations increasingly need governance around:
This places QA in a central role for AI oversight maturity.
| Early Stage | More Mature Stage |
|---|---|
| Generic audit focus | Risk-prioritized oversight |
| Retrospective review | Continuous evaluation |
| Variable interpretation | Shared oversight logic |
| Limited traceability | Documented rationale |
| Informal AI use | Governed AI workflows |
RBQM strengthens QA oversight when organizations align operational decisions, risk interpretation, and governance expectations across functions.
AI increases the importance of explainability, traceability, and human accountability.
